ProfileGDS5678 / 1438614_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 64% 66% 62% 66% 68% 70% 67% 72% 66% 66% 66% 66% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0818667
GSM967853U87-EV human glioblastoma xenograft - Control 23.8457664
GSM967854U87-EV human glioblastoma xenograft - Control 33.9976166
GSM967855U87-EV human glioblastoma xenograft - Control 43.7127762
GSM967856U87-EV human glioblastoma xenograft - Control 53.9846266
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1960268
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.333870
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0649967
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6084372
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0123766
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0063366
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0092466
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0142466
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3913470